Prevention of Iron Deficiency Anemia Post-delivery
A legfontosabb adatok
- Ki végzi
- NICHD Global Network for Women's and Children's Health
- Hol
- Banglades, Guatemala, India, Kenya, Kongó – Kinshasa, Pakisztán és Zambia8 helyszín, 7 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 3. fázis
- Résztvevők
- 4857 fő vett részt
- Kezdés
- 2023. máj. 30.
- Befejezés
- 2025. júl. 28.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Ferric carboxymaltose (FCM) and folic acid tablets
- Oral iron tablets and folic acid tablets
- A regiszteradat frissítve
- 2026. július 1.
Ki vehet részt
- Életkor
- 15 év – 49 év
- Nem
- Csak nők
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 17 feltétel megnézéseKevesebb
Ki vehet részt
- Established pregnancy ≥28 weeks gestational age by last menstrual period and/or clinical assessment and/or ultrasonography
- Age: 18 years (or lower limit age eligible*) to 49 years
- Confirmed moderate anemia (Hb 7.0 to 9.9 g/dL, 6-48 hour after delivery based on a venous blood sample on Hemocue®)
- Deliver in participating study hospital or health facility
- Able to provide informed consent
- Plans to remain in study area for at least 6 months postpartum
Ki nem vehet részt
- IV Iron infusion received in past 3 weeks
- Prior reaction to IV iron or oral iron or folic acid
- Blood transfusion already received or scheduled during the current hospital admission
- Major congenital anomaly prior to randomization
- Stillbirth or neonatal loss prior to randomization
- Positive malaria RDT prior to randomization (sub-Saharan African sites only)
- Contraindication to iron supplementation (some examples may include severe allergic states including asthma, hemolytic anemia, allergy, or severe infection)
- Known diagnosis of pre-existing depression or other psychiatric illness
- Known hemoglobinopathy (sickle cell disease or thalassemia)
- Any illness/condition requiring immediate medical care per physician's assessment
- Presenting with symptomatic anemia with dyspnea or fatigue and need for immediate correction
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
7 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
PRIORITY is designed as a 2-arm, randomized-controlled trial focused on postpartum women. The trial will recruit women who are diagnosed with moderate anemia based on a blood sample taken 6-48 hours after childbirth. A total of 4,800 eligible women, or 600 women per research site, will be consented and enrolled in the trial. The study hypothesizes that at 6 weeks postpartum, the incidence of achieving a non-anemic state (defined as Hb ≥11 g/dL) will be greater among women receiving a single-dose infusion of IV iron than among women receiving standard care with oral iron.
A vizsgálat 2 csoportja
- IV iron infusionA vizsgált kezelés
Participants randomized to the IV iron arm will receive a single-dose infusion of IV FCM, to be initiated between 6-48 hours after delivery. All randomized participants will receive 400 mcg of folic acid daily for 6 months postpartum.
Kezelés: Ferric carboxymaltose (FCM) and folic acid tablets
- Oral iron tabletsMár használt kezelés, összehasonlításként
Participants randomized to the oral iron arm will receive 60 mg elemental iron twice daily. Treatment will be initiated between 6-48 hours after delivery and prior to discharge from the facility. After discharge, each participant will take a treatment dose of twice daily for 6 weeks postpartum. At 6 weeks postpartum, serum Hb will be assessed and participants with Hb \< 7.0 g/dL will stop treatment, participants with Hb 7.0-11.9 g/dL will continue taking 60 mg elemental iron twice daily and participants with Hb \> 11.9 g/dL will take 60 mg elemental iron once daily. All randomized participants will receive 400 mcg of folic acid daily for 6 months postpartum.
Kezelés: Oral iron tablets and folic acid tablets
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Prevention of Iron Deficiency Anemia Post-delivery (PRIORITY Trial): A Randomized Controlled Trial of the Global Network for Women's and Children's Health Research
- A regiszteradat frissítve
- 2026. július 1.